The Hutchinson Sant? G-VIR? Glove Reduces the Risk of HIV Virus Transmission in Accidental Needlesticks by 99%, According to a Study Published in the Journal Surgery in February 2013[1] - Applied Clin

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
The Hutchinson Sant? G-VIR? Glove Reduces the Risk of HIV Virus Transmission in Accidental Needlesticks by 99%, According to a Study Published in the Journal Surgery in February 2013[1]


The Hutchinson Santé G-VIR® Glove Reduces the Risk of HIV Virus Transmission in Accidental Needlesticks by 99%, According to a Study Published in the Journal Surgery in February 2013[1]

PR Newswire

LIANCOURT, France, February 26, 2013 /PRNewswire/ --

The AIDS and hepatitis C viruses expose healthcare personnel to the risk of viral transmission (see the section Accidental exposure to blood: the contamination risks for healthcare personnel) as a result of:

  • accidental injuries during treatment (needles, scalpels, lancets, bone fragments, etc.)
  • contact with body fluids that contain blood

To view the Multimedia News Release, please click:

http://www.multivu.com/mnr/58703-Hutchinson-Sante

Thanks to a new patented technology developed by Hutchinson Santé, an innovative player in the fight against infection risks and in the comfort of healthcare personnel, the G-VIR® glove reduces the risk of contamination in cases of accidental exposure to blood, as shown in the study published in the February edition of  Surgery   (read the opinion of Prof. Charles Edmiston, surgeon and epidemiologist in - Milwaukee, United States-, co-author of the article).

The G-VIR® is an active protection glove, designed and developed to improve protection for carers against the risks of viral contamination. The G-VIR® is made up of 3 layers. The middle layer includes a disinfecting liquid dispersed as micro-droplets (see: G-VIR®, innovative technology for protecting carers): in the case of an accidental puncture, the disinfecting liquid is released on the inside and the outside of the sharp to inactivate the viruses.

The study presented in  Surgery   - the abstract of which   is attached  -   is t he first to test the efficacy of the G-VIR® in reducing the transmission of the AIDS virus - the studies carried out up to now had assessed the G-VIR®'s performance on a number of model viruses, such as BVDV, FIV, and HSV1[ 2] but never on HIV.

 

1. Charles E.Edmiston Jr: Evaluation of an antimicrobial surgical glove to inactivate live human immunodeficiency following simulated glove puncture, Surgery 2013; 153:225-332.

2. Bovine Virus Diarrhoea Virus, feline immunodeficiency virus, herpes simplex virus type 1


Video: http://www.multivu.com/mnr/58703-Hutchinson-Sante

SOURCE Hutchinson Sante

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
94%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
6%
View Results
Untitled Document

Click here